Moody's Affirms Ratings of Mylan (MYL) Amid Meda Acquisition Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mylan (MYL) Ratings Affirmed by Fitch Amid Meda Deal; Outlook Remains Stable
February 11, 2016 3:04 PM ESTFitch Ratings has affirmed the long-term Issuer Default Rating (IDR) of Mylan N.V. (Nasdaq: MYL), and the long-term ratings of its subsidiary Mylan, Inc., at 'BBB-' following the announcement that Mylan will acquire Meda A.B. (Meda) for approximately $9.9 billion. The Rating Outlook is Stable.
Mylan's ratings apply to approximately $7.3 billion of debt outstanding at Dec. 31, 2015. A full list of rating actions follows at the end of this release.
Fitch views the deal as strategically sound, strengthening Mylan's position in Western Europe while adding new important growth markets, including... More
Mylan (MYL) Shares Look to Stabilize After Pounding on 'Desparate' Meda Deal
February 11, 2016 11:09 AM ESTMylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall. Analysts called the deal,... More
Mylan to buy Swedish drugmaker Meda in $7.2 billion deal
February 10, 2016 4:49 PM ESTBy Natalie Grover
(Reuters) - Generic drugmaker Mylan NV (NASDAQ: MYL) said it would acquire Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company.
The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo (NYSE: PRGO).
Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer. That works out to be nearly twice Meda's last traded price, which had some analysts... More
